Lenalidomide
Active ingredient: Lenalidomide
In short: Lenalidomide capsules in combination with dexamethasone are indicated for the treatment of adult patients with multiple myeloma (MM). Lenalidomide capsules are indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
What is Lenalidomide used for?
Lenalidomide capsules in combination with dexamethasone are indicated for the treatment of adult patients with multiple myeloma (MM).
Lenalidomide capsules are indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT).
Lenalidomide capsules are indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Lenalidomide capsules are indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
Lenalidomide capsules in combination with a rituximab product, are indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).
Lenalidomide capsules in combination with a rituximab product, are indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).
Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with CLL outside of controlled clinical trials .
âš Boxed warning (FDA's strongest warning)
Embryo-Fetal Toxicity: Do not use lenalidomide capsules during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting lenalidomide capsule treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after lenalidomide capsule treatment . To avoid embryo-fetal exposure to lenalidomide, lenalidomide capsules are only available through a restricted distribution program, the Lenalidomide REMS program (5.2).
Information about the Lenalidomide REMS program is available at www.lenalidomiderems.com or by calling the REMS Call Center 1-888-423-5436.
Hematologic Toxicity (Neutropenia and Thrombocytopenia): Lenalidomide capsules can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with del 5q myelodysplastic syndromes had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q myelodysplastic syndromes should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. …
Lenalidomide dosage
The recommended starting dose of lenalidomide capsules is 25 mg orally once daily on Days 1-21 of repeated 28-day cycles in combination with dexamethasone. Refer to Section 14.1 for specific dexamethasone dosing. For patients greater than 75 years old, the starting dose of dexamethasone may be reduced . Treatment should be continued until disease progression or unacceptable toxicity.
In patients who are not eligible for auto-HSCT, treatment should continue until disease progression or unacceptable toxicity. For patients who are auto-HSCT-eligible, hematopoietic stem cell mobilization should occur within 4 cycles of a lenalidomide capsule-containing therapy .
Dose modification guidelines, as summarized in Table 1 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to lenalidomide capsules.
Platelet Counts
Thrombocytopenia in MM
When Platelets | Recommended Course
Days 1-21 of Repeated 28-day Cycle
Fall below 30,000/mcL | Interrupt lenalidomide capsule treatment, follow CBC weekly
Return to at least 30,000/mcL | Resume lenalidomide capsules at next lower dose. Do not dose below 2.5 mg daily
For each subsequent drop below 30,000/mcL | Interrupt lenalidomide capsule treatment
Return to at least 30,000/mcL | Resume lenalidomide capsules at next lower dose. Do not dose below 2.5 mg daily
Absolute Neutrophil Counts (ANC)
Neutropenia in MM
When Neutrophils | Recommended Course
Days 1-21 of Repeated 28-day Cycle
Fall below 1,000/mcL | Interrupt lenalidomide capsule treatment, follow CBC weekly
Return to at least 1,000/mcL and neutropenia is the only toxicity | Resume lenalidomide capsules at 25 mg daily or initial starting dose
Return to at least 1,000/mcL and if other toxicity | Resume lenalidomide capsules at next lower dose. Do not dose below 2.5 mg daily
For each subsequent drop below 1,000/mcL | Interrupt lenalidomide capsule treatment
Return to at least 1,000/mcL | Resume lenalidomide capsules at next lower dose. Do not dose below 2.5 mg daily
Following auto-HSCT, initiate lenalidomide capsule maintenance therapy after adequate hematologic recovery (ANC at least 1,000/mcL and/or platelet counts at least 75,000/mcL). The recommended starting dose of lenalidomide capsules is 10 mg once daily continuously (Days 1-28 of repeated 28-day cycles) until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, the dose can be increased to 15 mg once daily if tolerated.
Dose modification guidelines, as summarized in Table 2 below, are recommended to manage Grade 3 or 4 neutropenia or thrombocytopenia or other Grade 3 or 4 toxicity judged to be related to lenalidomide capsules. …
How to take Lenalidomide — instructions & advice from the label
Advise the patient to read the FDA-approved Patient labeling (Medication Guide)
Embryo-Fetal Toxicity: Advise patients that lenalidomide capsules are contraindicated in pregnancy . Lenalidomide capsules are a thalidomide analogue and can cause serious birth defects or death to a developing baby .
•Advise females of reproductive potential that they must avoid pregnancy while taking lenalidomide capsules and for at least 4 weeks after completing therapy.
•Initiate lenalidomide capsule treatment in females of reproductive potential only following a negative pregnancy test.
•Advise females of reproductive potential of the importance of monthly pregnancy tests and the need to use 2 different forms of contraception including at least 1 highly effective form, simultaneously during lenalidomide capsule therapy, during dose interruption and for 4 weeks after she has completely finished taking lenalidomide capsules. Highly effective forms of contraception other than tubal ligation include IUD and hormonal (birth control pills, injections, patch or implants) and a partner’s vasectomy. Additional effective contraceptive methods include latex or synthetic condom, diaphragm and cervical cap. …
Warnings & precautions
Do not take this medicine if: Lenalidomide capsules can cause fetal harm when administered to a pregnant female. Limb abnormalities were seen in the offspring of monkeys that were dosed with lenalidomide during organogenesis. This effect was seen at all doses tested. Due to the results of this developmental monkey study, and lenalidomide’s structural similarities to thalidomide, a known human teratogen, lenalidomide is contraindicated in females who are pregnant . If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential risk to a fetus .
Lenalidomide capsules are contraindicated in patients who have demonstrated severe hypersensitivity (e.g., angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide .
Lenalidomide capsules are a thalidomide analogue and are contraindicated for use during pregnancy. Thalidomide is a known human teratogen that causes life-threatening human birth defects or embryo-fetal death . An embryo-fetal development study in monkeys indicates that lenalidomide produced malformations in the offspring of female monkeys who received the drug during pregnancy, similar to birth defects observed in humans following exposure to thalidomide during pregnancy.
Lenalidomide capsules are only available through the Lenalidomide REMS program .
Females of reproductive potential must avoid pregnancy for at least 4 weeks before beginning lenalidomide capsule therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy. …
Lenalidomide side effects
The following clinically significant adverse reactions are described in detail in other sections of the prescribing information:
•Embryo-Fetal Toxicity
•Hematologic Toxicity
•Venous and Arterial Thromboembolism
•Increased Mortality in Patients with CLL
•Second Primary Malignancies
•Increased Mortality in Patients with MM When Pembrolizumab Is Added to a Thalidomide Analogue and Dexamethasone
•Hepatotoxicity
•Severe Cutaneous Reactions
•Tumor Lysis Syndrome
•Tumor Flare Reactions
•Impaired Stem Cell Mobilization
•Thyroid Disorders
•Early Mortality in Patients with MCL
•Hypersensitivity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Data were evaluated from 1613 patients in a large phase 3 study who received at least one dose of lenalidomide capsules with low dose dexamethasone (Rd) given for 2 different durations of time (i.e., until progressive disease [Arm Rd Continuous; N = 532] or for up to eighteen 28-day cycles [72 weeks, Arm Rd18; N = 540] or who received melphalan, prednisone and thalidomide (Arm MPT; N = 541) for a maximum of twelve 42-day cycles (72 weeks). The median treatment duration in the Rd Continuous arm was 80.2 weeks (range 0.7 to 246.7) or 18.4 months (range 0.16 to 56.7). …
Drug interactions
When digoxin was co-administered with multiple doses of lenalidomide capsules (10 mg/day) the digoxin Cmax and AUCinf were increased by 14%. Periodically monitor digoxin plasma levels, in accordance with clinical judgment and based on standard clinical practice in patients receiving this medication, during administration of lenalidomide capsules.
Erythropoietic agents, or other agents that may increase the risk of thrombosis, such as estrogen containing therapies, should be used with caution after making a benefit-risk assessment in patients receiving lenalidomide capsules .
Co-administration of multiple doses of lenalidomide capsules (10 mg/day) with a single dose of warfarin (25 mg) had no effect on the pharmacokinetics of lenalidomide or R- and S-warfarin. Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide capsule administration. It is not known whether there is an interaction between dexamethasone and warfarin. Close monitoring of PT and INR is recommended in patients with MM taking concomitant warfarin.
About this medicine
Lenalidomide capsules, a thalidomide analogue, are an immunomodulatory agent with antiangiogenic and antineoplastic properties. The chemical name is 3-(4-Amino-1-oxo 1,3-dihydro-2H-isoindol-2-yl) piperidine-2,6-dione and it has the following chemical structure:
The molecular formula for lenalidomide is C13H13N3O3, and the gram molecular weight is 259.27.
Lenalidomide is an off-white to pale yellow powder. It is soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL. Lenalidomide has an asymmetric carbon atom and can exist as the optically active forms S(-) and R(+), and is produced as a racemic mixture with a net optical rotation of zero.
Lenalidomide is available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 76f6c1e7-985b-43d9-892c-849df50ae80e. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate